Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Rigel (Nasdaq:RIGL) announced that CFO Dean Schorno will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m. ET in New York.

A live webcast and archived replay will be available via Rigel’s Investor Relations website.

News Market Reaction – RIGL

-0.65%

12 alerts

-0.65% Session close to close

$540.45M Market Cap

0.9x Rel. Volume

In the May 14 session, RIGL declined 0.65%, reflecting a mild negative market reaction. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlighted Rigel’s upcoming presentation at a major healthcare conference, positi...

Analysis

This announcement highlighted Rigel’s upcoming presentation at a major healthcare conference, positioning management to update investors on its hematology-oncology portfolio. Against a backdrop of recent licensing activity, profitable Q1 2026 results, and strong ARROW trial data, the event served as another investor-relations touchpoint. Investors may watch for any new commentary on VEPPANU integration, revenue trajectory, and pipeline progress shared during the company overview.

Key Figures

Conference date: May 19, 2026 Presentation time: 9:30 a.m. ET Company founding year: 1996 +2 more

5 metrics

Conference date May 19, 2026 RBC Capital Markets Global Healthcare Conference presentation

Presentation time 9:30 a.m. ET Scheduled time for Rigel company overview

Company founding year 1996 Rigel founding date noted in company description

Investor relations phone 650.624.1232 Rigel investor contact number in the release

Media contact phone 646.461.6387 Argot Partners media contact number in the release

Historical Context

5 past events · Latest: May 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 12	Licensing agreement	Positive	+12.1%	Exclusive global license for VEPPANU with significant milestones and royalties.
May 05	Q1 2026 earnings	Positive	-5.1%	Profitable Q1, strong revenues, reaffirmed 2026 guidance and clinical progress.
Apr 28	Earnings call notice	Neutral	+0.2%	Announcement of timing and access details for Q1 2026 results call.
Apr 07	Inducement grants	Neutral	+5.0%	Inducement RSU grants to six new non-executive employees under Nasdaq rules.
Mar 31	Clinical data update	Positive	+5.1%	Final ARROW trial data for GAVRETO in RET+ NSCLC published with strong efficacy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent material news (clinical data, licensing) often aligned with positive price moves, while earnings produced at least one notable divergence to the downside.

Recent Company History

Over the past few months, Rigel has reported profitable Q1 2026 results, closed a significant global license for VEPPANU, and highlighted strong ARROW trial data for GAVRETO with a 70% ORR. These events generally coincided with positive price reactions, except for earnings on May 5, which saw a -5.06% move despite constructive fundamentals. Today’s conference presentation fits into an active investor-relations cadence following substantial strategic and clinical updates.

Key Terms

hematologic disorders

1 terms

hematologic disorders medical

"focused on hematologic disorders and cancer, today announced"

Hematologic disorders are diseases that affect the blood and the organs that make blood, such as conditions causing low blood counts, abnormal clotting, or cancers of blood-forming cells. For investors, these disorders matter because they define markets for diagnostics, treatments and long-term care—think of them as problems in a city’s delivery and maintenance system: fixing them can create commercial opportunities, while persistent unmet needs can drive regulatory attention and spending.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m. ET in New York, NY.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
ir@rigel.com

Media:
David Rosen 
Argot Partners 
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-2026-rbc-capital-markets-global-healthcare-conference-302771835.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel (RIGL) present at the 2026 RBC Capital Markets Global Healthcare Conference?

Rigel will present on Tuesday, May 19, 2026, at 9:30 a.m. ET. According to Rigel, the presentation takes place in New York and will feature a company overview led by chief financial officer Dean Schorno.

Who is presenting for Rigel (RIGL) at the 2026 RBC Capital Markets Global Healthcare Conference?

Rigel’s chief financial officer, Dean Schorno, will present a company overview. According to Rigel, he will speak at the conference on May 19, 2026, at 9:30 a.m. ET in New York, highlighting the company’s business and pipeline.

How can investors access Rigel’s (RIGL) webcast for the 2026 RBC Capital Markets Global Healthcare Conference?

Investors can access a live webcast and archived recording through Rigel’s Investor Relations website. According to Rigel, users should connect to the site before the event to complete any necessary software downloads for smooth viewing.

What type of company is Rigel (RIGL) and what does it focus on?

Rigel is a commercial-stage biotechnology company focused on hematologic disorders and cancer. According to Rigel, the company discovers, develops, and provides novel therapies, supported by both marketed products and a pipeline of potential treatments.

Where is Rigel (RIGL) headquartered and when was it founded?

Rigel is based in South San Francisco, California, and was founded in 1996. According to Rigel, its work centers on therapies for hematologic disorders and cancer, supported by marketed products and an active development pipeline.

Where can investors find more information about Rigel’s (RIGL) products and pipeline?

Investors can visit www.rigel.com for information on marketed products and the development pipeline. According to Rigel, the website’s Investor Relations section also hosts the live webcast and archived recording of the 2026 RBC healthcare conference presentation.